Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07804004 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease

Name: A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease — clinical trial record (NCT07804004)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: CRSP-AID-502

StatusNot Yet Recruiting

PhasePhase 1/2

SponsorCRISPR Therapeutics

Started2026-09-15

View on ClinicalTrials.gov ↗

This is a single-arm, open-label, multicenter, ascending dose Phase 1/2 trial evaluating the safety and preliminary efficacy of CTX112 in adult participants with neurological autoimmune diseases (AIDs), including Progressive Multiple Sclerosis, relapsing Neuromyelitis Optica Spectrum Disorder, relapsing Myelin Oligodendrocyte Glycoprotein Antiody-Associated Disease, refractory AutoImmune Encephalitis, and refractory Stiff Person Syndrome

Trial Details

NCT Number	NCT07804004
Lead Sponsor	CRISPR Therapeutics
Conditions	Progressive Multiple Sclerosis (PMS), Neuromyelitis Optica, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Autoimmune Encephalitis, Stiff-Person Syndrome
Enrollment	220 participants
Start Date	2026-09-15
Primary Completion	2029-12-30 (estimated)
Study Completion	2029-12-30 (estimated)
Updated on ClinicalTrials.gov	2026-09-04